Portfolio

Collaborative biotech innovation

MTM catalyses the development of next-generation therapeutics for unmet medical needs. We are pushing the boundaries of drug discovery and development, making it faster and more effective.

Melio Bio

Leveraging human genetics for better cardiometabolic health

ThirtyFiveBio

Precision treatment of digestive system disorders

Pathios Therapeutics

Using human genetics to transform cancer outcomes

Grey Wolf Therapeutics

Advancing novel antigen modulation technology that controls T cells to guide the immune system.​
Working with MTM supports our focus on developing drugs for patients. Whether it is scientific input from the bioinformatics team, allowing us to interrogate human biology, or financial or company secretarial work that allow us to run an efficient and compliant operation, we are part of the same team.

James Westcott, PhD

CEO, ThirtyFiveBio

The culture of innovation and support within the MTM ecosystem enables Grey Wolf Therapeutics to achieve and surpass its goals, leveraging a network rich in expertise.  Notably, MTM’s bioinformatics team has played a pivotal role in advancing our mission. Their collaborative spirit and specialised knowledge have greatly strengthened our capabilities.

Andy Page

COO/CBO, Grey Wolf Theraputics

Transforming lives through collaborative innovation